No Data
No Data
Shareholders in Y-mAbs Therapeutics (NASDAQ:YMAB) Have Lost 74%, as Stock Drops 14% This Past Week
Y-mAbs to Present at the 43rd Annual J.P. Morgan Healthcare Conference
We're Hopeful That Y-mAbs Therapeutics (NASDAQ:YMAB) Will Use Its Cash Wisely
Clear Street Launches Healthcare & Biotechnology Equity Research
JonesTrading Maintains Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Maintains Target Price $23
Promising Preclinical Data on CD38-SADA Justifies Buy Rating for Y-Mabs Therapeutics